You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Through its Genasis imaging platform, ASI will also provide automation and image analysis capabilities to support the use of Kromatid's FISH probes.
Roche Pharmaceuticals will use Oncimmune's SeroTag infectious disease panel in a clinical trial for Actemra (tocilizumab) in COVID-19 patients.
MyHealthChecked's kit uses Yourgene Health's Clarigene SARS-CoV-2 PCR test and EKF Diagnostics' PrimeStore MTM sample collection device.
Novel Microdevices is developing a portable, sample-to-answer instrument that is designed to perform molecular testing on untreated patient samples.
COVID-19 surveillance contributed to sequencing revenue growth and helped Illumina beat analysts' top-line estimates, but it was not the primary growth driver.
For the three months ended March 31, the firm said that preliminary revenues for Q1 are expected to be $1.4 million compared with $3.2 million a year ago.
The Bruker-backed startup will make technology whose data could be complementary to both NGS-based Hi-C assays and spatial transcriptomics methods.
The company showed that its chip can detect SNPs in models of sickle-cell disease and amyotrophic lateral sclerosis, without the need for DNA amplification.
Invitae expects that Genosity's software and data management platform will allow it to quickly advance several oncology tests in development.
The genome engineering company has started shipping its Onyx platform commercially, including to the University of Liverpool's synthetic biology foundry GeneMill.
The DRP would be used to identify kidney cancer patients likely to benefit from dovitinib, a repurposed TKI for which Allarity plans to file an NDA this year.
The GenomeWeb Index underperformed the Dow Jones and the Nasdaq, but outperformed the Nasdaq Biotechnology Index last month.
The assay is Guardant Health’s first commercially available product for clinical management of early-stage tumors and is initially focused on colorectal cancer.
The firm's assay leverages reverse transcriptase quantitative PCR to amplify two separate regions of the HIV-1 genome to monitor HIV-infected patients.
The company said that it is on track to meet its goal of shaving $7.2 million in costs this year as it undertakes a recently announced restructuring plan.
The companies will integrate their respective technologies into a platform for clinical genetics services, including test ordering and virtual counseling.
Analyst Max Masucci told investors he believes the stock is worth owning now, regardless of uncertainty surrounding Illumina's plans to acquire Grail.
The company is planning to commercialize its cancer early detection technology initially in lung cancer and is working with NYU researchers to explore future expansions.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.
CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.
In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.